Skip to content

Study · Observational study · n = 27,406 · 2025

4 results

Effectiveness of semaglutide on survival outcomes in patients with type 2 diabetes and chronic kidney disease.

Kishimori T, Kato T, Wada A, Tani A, Yamaji R, Koike J, Iwasaki Y, Matsumoto T, Yagi T, Okada M

Open heart8 Jul 2025Cited by 1 (Europe PMC)

PMID40628673 (opens in a new tab)PMCIDPMC12243591 (opens in a new tab)DOI10.1136/openhrt-2025-003382 (opens in a new tab)PepBankPUB-40628673
Read at sourcePubMedAsk about this study
Jump to 4 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC. Results still quote short attributed sentences.

Results from this study4

4 results from studies that gave the peptide. 4 results from people.

  1. 01HumanObservational studyEfficacy outcome

    In propensity-matched adults with type 2 diabetes and chronic kidney disease, semaglutide was linked to a lower 3-year risk of all-cause death than sitagliptin (HR 0.76).

    In plain wordsIn adults with type 2 diabetes and kidney disease, semaglutide use was linked to a lower 3-year risk of death than sitagliptin.

    Peptide
    Semaglutide
    Outcome
    Decrease3-year all-cause death
    Study

    n = 27,406

    Comparator
    Sitagliptin
    Analysis
    Primary
    Outcome group
    Mortality · Cardiovascular
    Studied dose
    Dose not stated

    Measurements

    Hazard ratio
    0.76 HR
    all-cause death

    Source sentences

    Summary
    The 3-year risk of all-cause death in the semaglutide group relative to the sitagliptin group was significantly lower (7.2% (943/13 703) vs 9.5% (1196/13 703); p<0.001; HR, 0.76; 95% CI, 0.70 to 0.83).
    2 context sentences
    Summary · context
    This multicentre retrospective observational study using TriNetX, a global healthcare data platform.
    Summary · context
    After propensity score matching, 13 703 patients were included in each group.
  2. 02HumanObservational studyEfficacy outcome

    In propensity-matched adults with type 2 diabetes and chronic kidney disease, semaglutide was linked to a lower risk of acute heart failure than sitagliptin (HR 0.92).

    In plain wordsIn adults with type 2 diabetes and kidney disease, semaglutide use was linked to less acute heart failure than sitagliptin.

    Peptide
    Semaglutide
    Outcome
    DecreaseAcute heart failure
    Study

    n = 27,406

    Comparator
    Sitagliptin
    Analysis
    Secondary
    Outcome group
    Cardiovascular events · Cardiovascular
    Studied dose
    Dose not stated

    Measurements

    Hazard ratio
    0.92 HR
    acute heart failure

    Source sentences

    Summary
    Similarly, the semaglutide group was less likely to have acute HF (12.1% vs 13.1%; HR, 0.92; 95% CI, 0.86 to 0.98).
    2 context sentences
    Summary · context
    This multicentre retrospective observational study using TriNetX, a global healthcare data platform.
    Summary · context
    After propensity score matching, 13 703 patients were included in each group.
  3. 03HumanObservational studyEfficacy outcome

    In propensity-matched adults with type 2 diabetes and chronic kidney disease, semaglutide and sitagliptin did not differ significantly in acute myocardial infarction risk.

    In plain wordsIn adults with type 2 diabetes and kidney disease, semaglutide and sitagliptin users had similar heart attack risk.

    Peptide
    Semaglutide
    Outcome
    No significant changeAcute myocardial infarction
    Study

    n = 27,406

    Comparator
    Sitagliptin
    Analysis
    Secondary
    Outcome group
    Cardiovascular events · Cardiovascular
    Studied dose
    Dose not stated

    Measurements

    Hazard ratio
    1.01 HR
    acute myocardial infarction

    Source sentences

    Summary
    However, the risks of acute myocardial infarction and stroke in the semaglutide group relative to the sitagliptin group were not significant (9.6% vs 9.5%; HR, 1.01; 95% CI, 0.93 to 1.09 in acute myocardial infarction, and 9.2% vs 9.0%; HR, 1.02; 95% CI, 0.94 to 1.10 in stroke).
    2 context sentences
    Summary · context
    This multicentre retrospective observational study using TriNetX, a global healthcare data platform.
    Summary · context
    After propensity score matching, 13 703 patients were included in each group.
  4. 04HumanObservational studyEfficacy outcome

    In propensity-matched adults with type 2 diabetes and chronic kidney disease, semaglutide and sitagliptin did not differ significantly in stroke risk.

    In plain wordsIn adults with type 2 diabetes and kidney disease, semaglutide and sitagliptin users had similar stroke risk.

    Peptide
    Semaglutide
    Outcome
    No significant changeStroke
    Study

    n = 27,406

    Comparator
    Sitagliptin
    Analysis
    Secondary
    Outcome group
    Cardiovascular events · Cardiovascular
    Studied dose
    Dose not stated

    Measurements

    Hazard ratio
    1.02 HR
    stroke

    Source sentences

    Summary
    However, the risks of acute myocardial infarction and stroke in the semaglutide group relative to the sitagliptin group were not significant (9.6% vs 9.5%; HR, 1.01; 95% CI, 0.93 to 1.09 in acute myocardial infarction, and 9.2% vs 9.0%; HR, 1.02; 95% CI, 0.94 to 1.10 in stroke).
    2 context sentences
    Summary · context
    This multicentre retrospective observational study using TriNetX, a global healthcare data platform.
    Summary · context
    After propensity score matching, 13 703 patients were included in each group.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    11 Oct 2026, 00:04 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:06 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.